<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754871</url>
  </required_header>
  <id_info>
    <org_study_id>13180</org_study_id>
    <secondary_id>2008-003611-13</secondary_id>
    <nct_id>NCT00754871</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Characterization of Dienogest</brief_title>
  <official_title>A Double-blind, Randomized, Dose-controlled Study to Evaluate Pharmacodynamic Properties of Four Oral Doses of Dienogest (DNG) in 100 Healthy Young Female Volunteers Over a Period of Two Cycles up to a Maximum of 72 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be investigated what mechanism of action Dienogest has. The growth of the
      follicles, the endometrium, the hormones in the blood and the mucus that is produced by the
      cervix that will be looked upon. Four different dosages of Dienogest (0.5 mg, 1 mg, 2 mg and
      3 mg) will be investigated in healthy young women over two cycles, or up to a maximum of 72
      days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No primary variables defined, all variables are considered exploratory since no confirmatory statistical analysis planned</measure>
    <time_frame>No primary variables defined, all variables are considered exploratory since no confirmatory statistical analysis planned</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Course of gonadotropins (FSH, LH, P, E2)</measure>
    <time_frame>During pre-treatment and treatment cycles (3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>During pre-treatment and treatment cycles (3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grading of ovarian activity</measure>
    <time_frame>During pre-treatment and treatment cycles (3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on the cervix and the cervical mucus</measure>
    <time_frame>During pre-treatment and treatment cycles (3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression profile of endometrial biopsies and in blood</measure>
    <time_frame>once in pre-treatment and during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of DNG in serum</measure>
    <time_frame>During pre-treatment and treatment cycles (3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>During pre-treatment and treatment cycles (3 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Pharmacodynamics</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dienogest (81150037)</intervention_name>
    <description>daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dienogest (81150231)</intervention_name>
    <description>daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dienogest (SH T00660A)</intervention_name>
    <description>daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dienogest (81150746)</intervention_name>
    <description>daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Body-Mass-Index (BMI): 18 - 30 kg/mÂ²

          -  Healthy female volunteers

          -  Age 18-35 years (smoker not older than 30 years, inclusive)

          -  At least 3 months since delivery, abortion or lactation

          -  Willingness to use non-hormonal methods of contraception during entire study

        Exclusion Criteria:

          -  Contraindications for use of progesterone-only pills or combined oral contraceptives
             (e.g. history of venous/arterial thromboembolic disease)

          -  Use of systemic or topical medications or substances which oppose the study objectives
             or which might influence them within 4 weeks prior to start of the pre-treatment cycle

          -  Clinically relevant findings (blood pressure, physical and gynecological examination,
             laboratory examination)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here and search for websynopsis results provided by Bayer</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu</url>
    <description>Click here and search for product information by EMA</description>
  </link>
  <results_reference>
    <citation>Klipping C, Duijkers I, Remmers A, Faustmann T, Zurth C, Klein S, Schuett B. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J Clin Pharmacol. 2012 Nov;52(11):1704-13. doi: 10.1177/0091270011423664. Epub 2011 Nov 29.</citation>
    <PMID>22128200</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dienogest</mesh_term>
    <mesh_term>Nandrolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

